Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BB-401

Oligonucleotide (siRNA) · Gene silencing: EGFR · developed by Benitec Biopharma

Phase 2 Most advanced trial (none active)
BNTC Developer
1 Registered trials

What is BB-401?

BB-401 is a plasmid DNA expression vector encoding a short hairpin RNA against EGFR. After intratumoral administration it is taken up by tumor cells, where the shRNA is processed into siRNA that binds EGFR RNA and blocks EGFR protein expression. It is studied in head and neck squamous cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Targets
EGFR
Mechanism
Gene silencing: EGFR
Pathways
RNA interference, EGFR mRNA translation
Therapy area
Oncology
Developer
Benitec Biopharma, Inc. (BNTC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03433027 Phase 2 Head and Neck Squamous Cell Carcinoma Completed BNTC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Head and Neck Squamous Cell Carcinoma

Other drugs acting on EGFR

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BNTC page.

Follow BNTC, the company behind BB-401

See BNTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BNTC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.